Tech Company Financing Transactions
Singulex Funding Round
On 1/14/2009, Singulex landed $19 million in Series E funding from Rally Ventures, Fisk Ventures and OrbiMed.
Transaction Overview
Company Name
Announced On
1/14/2009
Transaction Type
Venture Equity
Amount
$19,000,000
Round
Series E
Investors
Proceeds Purpose
Singulex will use the funds from this financing to deploy its product and services in the emerging molecular clinical diagnostic market. Initially, the company will focus on cardiovascular disease risk diagnostics using its assay platform for the biomarker c Troponin I (cTnI), a well-validated marker for cardiac necrosis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1701 Harbor Bay Pkwy. 200
Alameda, CA 94502
USA
Alameda, CA 94502
USA
Phone
Website
Email Address
Overview
Singulex is an early stage biotechnology company with research and development laboratories in St. Louis and commercial operations in Hayward, California.Singulex has obtained exclusive license to all intellectual property around its core technology and has further fortified this position.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guido Baechler
Chief Scientific Officer
John Todd
VP - Bus. Development
Thomas Schlumpberger
VP - Finance
Brandon Hants
VP - Human Resources
Byron Clendenen
VP - Marketing
Jessica McCarthy
VP - Operations
Mark Stene
VP - R & D
Jeffrey Bishop
VP - Regulatory Affairs
Karen Richards
VP - Sales
Robert Brousseau
Browse more venture capital transactions:
Prev: 1/14/2009: Ubicom venture capital transaction
Next: 1/14/2009: United Sample venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs